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A B S T R A C T
Background: Two major changes to the staging of oral cavity squamous cell carcinoma (OCSCC) were adopted in
TNM8: (1) depth of invasion is now used for T staging and (2) extranodal extension for N staging. The aim of this
study was to evaluate if TNM8 stratifies OCSCC patients more accurately than TNM7 based on overall survival
(OS) statistics and hazard discrimination.
Methods: Retrospective study of 297 patients with OCSCC who underwent surgery at our institution. Clinical and
pathological data were previously populated from review of medical charts and histological reports. Slides were
re-reviewed for depth of invasion measurements. Patients were staged using both TNM7 and TNM8 with overall
survival statistics analysed.
Results: Overall 118 patients (39.7%) were upstaged using TNM8. Both TNM7 and TNM8 stage categories were
highly significant for OS (all p values < 0.0001). Hazard discrimination analysis showed that TNM7 could only
differentiate stage III from stage IV disease with significance (OS p = 0.01). In comparison TNM8 could dis-
tinguish between stage II and III disease (OS p = 0.047) and between stage III and IV disease (OS p = 0.004).
Subsite analysis suggested that both editions of the staging system perform best for tongue primaries.
Conclusions: Although TNM8 showed improved hazard discrimination in comparison to TNM7, problems with
discriminative ability persisted with 8th edition staging criteria. Large scale validation studies will be required to
direct future refinement of the staging rules and to establish if the continued use of a single staging system for all
oral cavity subsites is appropriate.
Introduction
The goals of cancer staging systems include the categorization of
patients with similar prognosis, which may in turn inform treatment
planning, comparison of outcomes, and research. Key components of an
ideal cancer staging system include hazard discrimination, whereby
each staging subgroup should have different survival to the group
above and below, and hazard consistency, meaning that patients within
the same subgroup should have similar survival [1]. In an attempt to
improve the hazard discrimination and hazard consistency of oral
cancer staging, the American Joint Committee on Cancer Control
(AJCC) have made two significant changes to the most recent 8th edi-
tion staging. These changes include the incorporation of depth of in-
vasion (DOI) into the T-category, and extranodal extension (ENE) into
the N-category [2].
There is a good body of evidence to support these changes in TNM
classification. Numerous studies have shown DOI to be a significant
predictor of outcome in oral cavity squamous cell carcinoma (OCSCC)
[3–10]. The definitive reference study on which the cut-off points for
DOI were chosen by the AJCC was a retrospective analysis undertaken
by the International Consortium for Outcome Research in Head and
Neck Cancer (ICOR), of 3149 OCSCC patients treated at 11 cancer
centres, between 1990 and 2011 [6]. There is also an abundance of
evidence to support the negative impact of ENE on survival in head and
neck cancer including in OCSCC [11–14].
Prior to implementation the revised T and N categories were vali-
dated by the AJCC using a combined Memorial Sloan Kettering Cancer
Centre-Princess Margaret Hospital (MSKCC-PMH) dataset of 1788
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patients. The final step was to analyse the interplay between the pro-
posed T and N categories by examining the stage groupings. When the
7th edition stage groupings were applied to the proposed 8th edition T
and N criteria it was not possible to discriminate between stage II and
stage III disease based on overall survival statistics. Re-analysis fol-
lowing adjustment of the stage groupings yielded improved hazard
discrimination. However, the adjusted stage groupings could not be
validated using cancer registry data due to lack of availability of DOI
measurements and ENE status in the National Cancer Database.
Therefore, although institutional data (MSKCC-PMH dataset) supported
amendment of the stage groupings, the AJCC elected to leave them
unchanged pending future validation [2].
The aim of this study was to evaluate if TNM8 stratifies OCSCC
patients more accurately than TNM7 based on overall survival statistics
and hazard discrimination.
Patients and methods
This was a retrospective study of 297 patients with primary OCSCC
who underwent definitive surgical treatment at the South Infirmary
Victoria Hospital between 2000 and 2016. Patients were identified from
a pre-existing database. Patients with recurrent cancers, second primary
Head and Neck cancers, synchronous primary cancers, or who had
undergone previous neck irradiation, were excluded. Ethical approval
for the study was obtained from the Cork Clinical Research Ethics
Committee. Clinical and pathological data including ENE status were
previously populated from review of medical charts and histological
reports. In cases where ENE was not recorded in the original pathology
report, original pathology slides were reviewed for determination of
same. Original pathology slides were re-reviewed for DOI measure-
ments by 2 pathologists at a mulitheaded microscope and the consensus
DOI measurement utilised for 8th edition staging. DOI was measured by
dropping a plumbline from the basement membrane of adjacent intact
squamous mucosa to the deepest point of tumour invasion [2]. All
patients were then re-staged using both TNM7 and TNM8, according to
the data in the final study database.
Survival was calculated from the time of surgery to the time of death
or last follow up in clinic. Patients dying with recurrence or otherwise
uncontrolled cancer were considered to have died from disease.
Patients dying from medical complications in the first month after
surgery were also considered to have died due to cancer. Statistical
analysis was performed using XLSTAT (Addinsoft). Survival curves
were analysed using Kaplan-Meier method and Log-Rank test. Hazard
ratios were calculated using Cox proportional hazards modelling.
Results
The study cohort comprised of 297 patients (199 males).
Clinicopathological and demographic features of the study population
are shown in Table 1. Tongue (39%), and floor of mouth (FOM) (28%)
were the most frequent subsites.
Within the T-classification, 114 (38.4%) patients were upstaged,
with 70 moving from T1 to T2, 32 from T2 to T3 and 12 from T3 to T4.
No patient was downstaged. Within the N-classification, 47 of 101 node
positive patients (46.5%) were upstaged with 8 migrating from N1 to
N2a, and 39 migrating from N2b and N2c to N3b. When the stage
groupings were applied, 118 patients (39.7%) were upstaged using
TNM8. No patient was downstaged. The largest migration (51 patients)
was from stage I to II. Of note, using TNM7, no patient had stage IVB
disease, which at that time required a T4b primary tumour or a nodal
metastasis> 6 cm in size. TNM8 resulted in the migration of 39 cases
(13.1% of the overall cohort) into stage IVB due the presence of ENE.
See Table 2 for stage re-distribution.
Mean and median follow-up were 45 and 33 months respectively.
149 patients died, of whom 82 died from cancer. 7 additional patients
who died within the first postoperative month from medical
complications were considered to have died from disease.
Both TNM7 and TNM8 staging were highly predictive of disease
specific survival (DSS) and OS on Kaplan-Meier analysis (all p va-
lues < 0.0001) (Table 3 and Fig. 1).
When hazard discrimination was analysed TNM7 could distinguish
between stage III and stage IV disease based on both OS and DSS
(p = 0.01 and p = 0.001, respectively), but could not discriminate
between other contiguous stage groupings. TNM8 could also distinguish
between stage III and IVA/IVB disease (OS p = 0.004, DSS p = 0.003),
but could not discriminate between stage III and IVA and neither could
it discriminate between stage I and II. However, TNM8 could differ-
entiate between stage II and III disease based on OS, but not DSS
(p = 0.047 and 0.15 respectively).
In contrast to our findings, the AJCC validation study of TNM8
failed to discriminate between stage II and III disease based on OS, but
re-analysis following adjustment of the stage groupings generated im-
proved hazard discrimination. Of note in our cohort the OS p-value of
0.047 for stage II versus III disease only just reached significance.
Therefore, similar to the AJCC, we adjusted the stage groupings in an
attempt to improve discriminative ability between stage II and III. Two
approaches were utilised: (1) patients with T3N0 disease were moved
from stage III to stage II; and (2) patients with T1N1 and T2N1 disease
were moved from stage III to stage II. The data were then re-analysed.
When T3N0 cases were re-categorised as stage II, the p-value for stage II
versus III disease based on OS became non-significant (p = 0.43). In
contrast when T1N1 and T2N1 cases were reclassified as stage II, the p-
values for stage II versus III disease for OS and DSS were 0.0001 and
0.001 respectively. However, discriminative ability for stage III versus
Table 1
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IV disease was then lost (OS p = 0.30, DSS p = 0.28) (Table 3 and
Fig. 2).
Some aspects of the stage grouping survival results were reflected in
sub-analysis of the T and N categories. TNM8 could not differentiate
between T1 and T2 disease based on OS or DSS mirroring the inability
to discriminate stage I and II disease, whereas TNM7 could discriminate
between T1 and T2 with respect to DSS, but not OS. Overall survival
statistics were significant for T2 versus T3 cases using both systems, but
not for T3 versus T4. Within the N categories TNM8 could not dis-
criminate N1 from N2 disease. OS hazard discrimination was significant
for all other nodal categories using both staging editions (Table 4).
Finally, a subanalysis was undertaken to ascertain if the staging
system performs differentially depending on oral cavity primary sub-
site. Tongue and non-tongue subsites were analysed separately. For
tongue primaries, OS of T1 versus T2 cases could be separated with
statistical significance using TNM8 (HR 3.48, 95% CI 1.20, 10.12;
p = 0.02) and was just outside significance for TNM7 (HR 2.05, 95%
0.99, 4.24; p = 0.05). For DSS, only TNM8 was significant (HR 4.55,
95% CI 1.04, 19.89; p = 0.03). For stage I versus stage II tongue
cancers, the discriminative ability of both TNM7 (HR 2.69, 95% CI
0.99, 7.34, p = 0.05 for OS; and HR 2.65, 95% CI 0.79, 8.87, p = 0.10
for DSS), and TMN8 (HR 2.80, 95% CI 0.77, 10.19, p = 0.10 for OS;
and HR 2.51, 95% CI 0.51, 12.47, p = 0.24 for DSS) were outside
significance. For non-tongue cancers, T1 versus T2 disease could not be
discriminated by either system. Using TNM7, there was no survival
difference between stage I and stage II non-tongue cancers. Using TNM
8, stage I patients had paradoxically worse survival than stage II pa-
tients based on OS (HR 0.52, 95% CI 0.28, 0.99, p = 0.04), due to late
divergence of survival curves. There was no significant difference for
DSS. (Supplementary Table 1, Fig. 3).
Discussion
The 8th edition of the AJCC staging manual for oral cavity cancer
represents a significant advance over previous versions, incorporating
as it does for the first time DOI of the primary tumour into T staging,
Table 2
Stage re-distribution using TNM8 versus TNM7.
TNM8
Stage I Stage II Stage III Stage IVA Stage IVB Total
TNM7 Stage I 63 (55.3%) 51 (44.7%)* 0 0 0 114 (38.4%)
Stage II 0 31 (64.6%) 17 (35.4%)* 0 0 48 (16.2%)
Stage III 0 0 33 (75%) 11 (25%)* 0 44 (14.8%)
Stage IVA 0 0 0 52 (57.1%) 39 (42.9%)* 91 (30.6%)
Total 63 (21.2%) 82 (27.6%) 50 (16.8%) 63 (21.2%) 39 (13.1%)
* Numbers upstaged using TNM8
Table 3
p-values for hazard discrimination (Log-Rank test) between contiguous stage groupings, TNM7 and TNM8 (Log-rank test).
Overall Survival TNM7 TNM8 TNM8 with T3N0 in Stage II TNM8 with T1N1 & T2N1 in Stage II
Stage I v II 1.13 (0.67, 1.93) p = 0.64 0.79 (0.46, 1.35) p = 0.39 0.94 (0.57, 1.55) p = 0.81 0.77 (0.46, 1.31) p = 0.34
Stage II v III 1.50 (0.81, 2.80) p = 0.20 1.74 (1.00, 3.03) p = 0.047 1.32 (0.66, 2.64) p = 0.43 2.69 (1.49, 4.78) p = 0.001
Stage III v IV (all) 1.89 (1.14, 3.13) p = 0.01 2.03 (1.24, 3.32) p = 0.004 2.45 (1.22, 4.95) p = 0.01 1.32 (0.78, 2.26) p = 0.30
Stage III v IVA 1.89 (1.14, 3.13) p = 0.01 1.42 (0.82, 2.45) p = 0.21 1.66 (0.79, 3.48) p = 0.17 0.94 (0.52, 1.68) p = 0.81
Stage IVA v IVB 1.58 (2.57, 4.22) p < 0.0001
Disease Specific Survival TNM7 TNM8 TNM8 with T3N0 in Stage II TNM8 with T1N1 & T2N1 in Stage II
Stage I v II 1.63 (0.79, 3.37) p = 0.19 1.38 (0.59, 3.23) p = 0.46 1.78 (0.80, 3.96) p = 0.15 1.23 (0.53, 2.86) p = 0.62
Stage II v III 1.06 (0.46, 2.45) p = 0.90 1.70 (0.82, 3.52) p = 0.15 0.80 (0.28, 2.31) p = 0.68 3.51 (1.65, 7.46) p = 0.001
Stage III v IV (all) 2.90 (1.47, 5.74) p = 0.001 2.42 (1.32, 4.46) p = 0.003 4.00 (1.44, 11.10) p = 0.004 1.41 (0.75, 2.65) p = 0.28
Stage III v IVA 2.90 (1.47, 5.74) p = 0.001 1.55 (0.78, 3.08) p = 0.21 2.60 (0.89, 7.62) p = 0.07 0.86 (0.42, 1.74) p = 0.67
Stage IVA v IVB 3.35 (1.90, 5.89) p < 0.0001
Fig. 1. Overall survival according to stage groupings for AJCC 7th edition (left) and 8th edition (right).
H. Jawad, et al. Oral Oncology 111 (2020) 105021
3
and ENE into N staging. Both of these parameters have been shown
through an abundance of data to be significant prognosticators in
OCSCC. However, although TNM8 has been shown to be an improve-
ment over the previous edition, there is still a lack of data regarding the
stage groupings. In the initial validation study undertaken by the AJCC,
it was found that the 7th edition stage groupings applied to the 8th
edition T and N categories could not discriminate between stage II and
III disease. However, the stage groupings were left unaltered pending
additional validation data [2]. A further issue that has complicated the
introduction of the 8th edition staging is that since its initial publication
significant corrections and updates have been issued. The most im-
portant of these were (1) to correct the erroneous upstaging of tumours
≤2 cm in diameter and with DOI > 10 mm from T1 to T3, and (2) to
incorporate DOI criteria into the T4 category, which had originally been
omitted [15]. Consequently, the majority of groups to date who have
published on the prognostic ability of the AJCC 8th edition have used
incorrect versions of the staging system and therefore the results of
these early studies must be interpreted with caution [16].
In a more recently published study, Sridharan et al applied the
corrected 8th edition staging criteria to a cohort of 494 patients with
early stage oral tongue SCC (tumours ≤ 4 cm and pathologically node
negative). Overall 37.9% of patients were upstaged, with 34.5% up-
staged from pT2 (stage II) to pT3 (stage III). However, the latter was not
associated with improved local or locoregional control supporting the
AJCC’s conclusion that the categories of stage II and III disease may
require adjustment in future iterations of the staging system [16].
Amit et al also evaluated the prognostic ability of the corrected
version of TNM8 in early tongue cancer. They restricted their cohort to
7th edition T1 and T2 tumours with both node negative and positive
disease. 25% of the 244 patients in this study were upstaged. Overall
stage using TNM8 correlated significantly with both OS and DSS on
multivariate analysis, but TNM7 did not. The 8th edition also showed
better hazard discrimination compared with the 7th edition including
between stage II and III disease. When the T and N categories were
evaluated separately the only significant survival difference was seen in
patients upstaged from T2 to T3 disease, suggesting that the improved
performance of TNM8 compared to TNM7 was due to the effect of DOI.
The authors postulate that ENE may have lacked impact in their cohort
due to the low rate of nodal disease in early stage tongue cancer and/or
the modifying effect of adjuvant chemotherapy [17].
Garcia et al took a different approach. They restricted their analysis
to cases with nodal metastases in a retrospective study of 1188 patient
with Head and Neck SCC who underwent neck dissection, of whom 270
(23.8%) had oral cavity primaries. Overall 50.1% were node positive, of
whom 50.5% were upstaged due to the presence of ENE, with 20.9% of
patients upstaged from pN1 to pN2a and 58.4% from pN2 to pN3b. The
8th edition pN categories showed improved hazard discrimination
compared to the 7th edition [18].
In contrast to the studies above we placed no restrictions on either
tumour stage or oral cavity subsite for eligibility in our cohort of 297
patients. Both TNM7 and TNM8 highly correlated with DSS and OS.
TNM8 showed improved hazard discrimination in comparison to
TNM7. In contrast to the AJCC we found that the 8th edition could
differentiate between stage II and III disease based on OS, but not DSS
(p = 0.047 and 0.15 respectively). However, issues with discriminative
ability persisted with the 8th edition including failure to distinguish
Fig. 2. Overall survival according to stage groupings for proposed modifications to AJCC 8th edition stage groupings, T3N0 in stage II (left) and T2N1 in stage II.
Table 4
Hazard discrimination (Hazard ratios with 95% confidence interval, and p-value for log-rank test) for contiguous T and N categories, TNM7 and TNM8.
Overall Survival TNM7 TNM8
Hazard ratio p-value Hazard ratio p-value
T1 v T2 1.37 (0.90, 2.08) 0.14 0.95 (0.60, 1.52) 0.85
T2 v T3 2.30 (1.26, 4.20) 0.005 1.98 (1.17, 3.34) 0.009
T3 v T4 0.84 (0.46, 1.53) 0.56 1.45 (0.97, 2.45) 0.15
N0 v N1 2.21 (1.28, 3.82) 0.003 2.30 (1.29, 4.09) 0.004
N1 v N2 2.08 (1.20, 3.60) 0.007 0.74 (0.36, 1.63) 0.43
N2 v N3 3.84 (1.87, 7.90) < 0.0001
Disease Specific Survival TNM7 TNM8
Hazard ratio p-value Hazard ratio p-value
T1 v T2 1.76 (1.01, 3.07) 0.04 1.61 (0.80, 3.24) 0.17
T2 v T3 1.88 (0.86, 4.13) 0.11 2.15 (1.14, 4.08) 0.02
T3 v T4 1.22 (0.57, 2.61) 0.61 1.51 (0.82, 2.78) 0.19
N0 v N1 1.89 (0.91, 3.90) 0.08 2.06 (0.97, 4.34) 0.06
N1 v N2 2.80 (1.41, 5.57) 0.002 0.59 (0.20, 1.73) 0.33
N2 v N3 6.93 (2.64, 18.19) < 0.0001
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between stage I and II disease and between stage III and IVA disease.
Furthermore, our attempts to improve hazard discrimination by ad-
justing the stage groupings were unsuccessful. The latter finding is
unsurprising when sub-analysis of T and N categories is considered. We
were unable to replicate the findings of the AJCC validation study
which demonstrated significant survival differences between all con-
tiguous T and N categories [2]. Instead we found that TNM8 could not
distinguish T1 and T2 disease, T3 and T4 disease or N1 and N2 disease.
A potential explanation for the difference in our results in com-
parison to the AJCC validation study is variation in tumour subsite.
Many of the papers already published validating the 8th edition staging
are comprised mostly or exclusively of tongue cancers [16,17]. How-
ever, there is evidence that tumour subsite within the oral cavity in-
fluences the prognosis of OCSCC. Recent data from the Surveillance,
Epidemiology, and End Results (SEER) database for the period
2009–2015 reported a 5 year relative survival of 66.4% for tongue,
51.7% for FOM, 89.7% for lip and 59% for gum and other mouth pri-
maries [19]. The subsite breakdown of the combined MSKCC-PMH
dataset used by the AJCC to validate the 8th edition T and N categories
and stage groupings is not listed in the staging manual, however, it is
likely that tongue cases comprised the predominant subsite. In a paper
published by the MSKCC group in 2012 analysing changing trends in
smoking and alcohol consumption in 1617 patients with oral cavity
SCC, 49% had tongue primaries and 16% FOM primaries [20]. Like-
wise, in a cohort of surgically resected oral cavity cancer patients ex-
tracted from the National Cancer Database covering the period 2009 to
2013, 51.1% were tongue primaries and 15.8% were FOM primaries
(n = 16,246) [21]. The National Cancer Database captures approxi-
mately 70% of all newly diagnosed cancers in the USA [22], and is
therefore likely to provide an accurate reflection of oral cancer subsite
in North America. In contrast, our subsite distribution is strikingly
different with a much higher representation of FOM primaries at 28%,
and less tongue cases at 39%. Notably, sub-analysis confirmed that in
contrast to the findings in our overall cohort, both TNM7 and 8 could
separate T1 and T2 tongue cases, but not non-tongue cases. TNM7 could
also separate stage I and II tongue primaries, the 8th edition could not.
However, the latter finding may have been due to lack of power given
the smaller numbers of stage I and II cases using TNM8 staging rules.
Our study has a number of limitations including its retrospective
nature and wide timeframe. A further limitation is the lack of balance
between groups in our cohort, whereby relatively equal numbers of
subjects should ideally be present in each stage grouping to facilitate
validation of the staging system [1]. In our study population the per-
centage of subjects in each stage group varied from 14.8% to 38.4%
using TNM7 and from 16.8% to 34.3% for stage IVA&B combined using
TNM8 (see Table 2). In particular stage III tumours were under-re-
presented. Also, our subsite analysis was limited by small numbers.
Finally slides were not re-reviewed to assign ENE status, but instead this
parameter was extracted from the histology reports, excepting cases
where this parameter had not been recorded in the original report. We
also included patients with short survival, however, we felt that the
inclusion of such patients in this study was appropriate, as advanced
stage at the time of surgery may be a risk factor for early postoperative
death. On the other hand, major strengths included the re-review of all
slides for re-measurement of DOI according to TNM guidelines, so en-
suring that patients were as accurately staged as possible by TNM8.
Conclusion
Both 7th and 8th edition AJCC stage categories for OCSCC corre-
lated significantly with survival outcomes in our study cohort. Although
TNM8 showed superior hazard discrimination in comparison to TNM7,
deficiencies persisted with 8th edition staging rules including inability
to distinguish between stage I and II disease, between stage III and IVA
disease, and between contiguous T and N categories. It is possible that
some of the differences in the present study between the AJCC vali-
dation study and other studies may have been in part related to dif-
fering proportions of tongue versus FOM subsite, suggesting that further
work in is required to investigate impact of subsite on the prognostic
value of DOI, ENE, and the 8th edition TNM staging.
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